This is a heavily interactive web application, and JavaScript is required. Simple HTML interfaces are possible, but that is not what this is.
Post
Hidehito HORINOUCHI
hhorinouchi.bsky.social
did:plc:pwbuf4hieo24wlhs7d7fmfhl
⏰NOW OUT‼️ #ELCC25
🔥MARIPOSA🦋: Amivantamab plus lazertinib vs osimertinib in 1L EGFRm advanced NSCLC: Final OS
🎙️Prof. James Yang
🎯OS HR 0.75 (95%CI: 0.61-0.92)
🎯Seems like extending the OS for 1️⃣2️⃣ months
✅NCT04487080
#LCSM #EGFR
@oncoalert.bsky.social
@myesmo.bsky.social
@iaslc.bsky.social
2025-03-26T17:27:23.810Z